EP1305021A4 - Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition - Google Patents
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the compositionInfo
- Publication number
- EP1305021A4 EP1305021A4 EP01946709A EP01946709A EP1305021A4 EP 1305021 A4 EP1305021 A4 EP 1305021A4 EP 01946709 A EP01946709 A EP 01946709A EP 01946709 A EP01946709 A EP 01946709A EP 1305021 A4 EP1305021 A4 EP 1305021A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- dosage forms
- therapeutic agents
- controlled release
- forms including
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21383200P | 2000-06-23 | 2000-06-23 | |
US213832P | 2000-06-23 | ||
US21711000P | 2000-07-10 | 2000-07-10 | |
US217110P | 2000-07-10 | ||
US22321200P | 2000-08-04 | 2000-08-04 | |
US223212P | 2000-08-04 | ||
PCT/US2001/020134 WO2002000213A1 (en) | 2000-06-23 | 2001-06-22 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1305021A1 EP1305021A1 (en) | 2003-05-02 |
EP1305021A4 true EP1305021A4 (en) | 2009-09-23 |
Family
ID=27395915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01946709A Withdrawn EP1305021A4 (en) | 2000-06-23 | 2001-06-22 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1305021A4 (en) |
JP (1) | JP2004501190A (en) |
KR (1) | KR20030013460A (en) |
AU (2) | AU6872201A (en) |
CA (1) | CA2412490A1 (en) |
CZ (1) | CZ2003199A3 (en) |
EA (1) | EA200300046A1 (en) |
HU (1) | HUP0301465A3 (en) |
IL (1) | IL153497A0 (en) |
MX (1) | MXPA02012793A (en) |
WO (1) | WO2002000213A1 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608640B2 (en) | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
MXPA04001388A (en) * | 2001-08-16 | 2004-05-27 | Oregon State | Expandable gastric retention device. |
BE1015608A6 (en) | 2003-07-15 | 2005-06-07 | Messadek Jallal | TREATMENT arteritis. |
US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
ATE347358T1 (en) * | 2003-04-17 | 2006-12-15 | Jallal Messadek | FLOATING ORAL FORMULATIONS WITH CONTROLLED RELEASE OF BETAIN |
NZ546662A (en) * | 2003-10-20 | 2009-03-31 | Teva Pharma | Composition and dosage form for sustained effect of levodopa |
JP2005132803A (en) * | 2003-10-31 | 2005-05-26 | Ono Pharmaceut Co Ltd | Solid pharmaceutical preparation staying in stomach |
TW200533391A (en) * | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
FR2874325B1 (en) * | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | PHARMACEUTICAL COMPOSITION IN THE FORM OF A GASTRIC RESISTANCE COMPRESSOR CONTAINING ALFUZOSIN |
WO2006050581A2 (en) | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
EP2242489A1 (en) | 2005-02-15 | 2010-10-27 | Jallal Messadek | Combination therapeutic compositions and method of use |
RU2007143510A (en) | 2005-04-27 | 2009-06-10 | Яллал МЕССАДЕК (BE) | INSULIN COMPOSITIONS |
NL2000281C2 (en) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Solid pharmaceutical compositions containing pregabalin. |
ZA200810834B (en) * | 2006-05-31 | 2010-03-31 | Solvay Pharm Gmbh | Long term 24 hour intestinal administration of levodopa/carbidopa |
EP1872775A1 (en) * | 2006-06-29 | 2008-01-02 | Polichem S.A. | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
AR062659A1 (en) * | 2006-09-08 | 2008-11-26 | Drug Tech Corp | COMPOSITION OF LEVODOPA SUSTAINED RELEASE AND METHOD FOR USE |
EP2066303B1 (en) * | 2006-09-26 | 2016-05-04 | Plensat, LLC | System for treatment of eating disorders |
US20100112053A1 (en) | 2007-01-15 | 2010-05-06 | Kissei Pharmaceutical Co., Ltd. | Gastric retention-type sustained-release levodopa preparation |
KR20080076382A (en) * | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | Controlled-release preparation containing cilostazol and process for the preparation thereof |
DE102007026037A1 (en) * | 2007-06-04 | 2008-12-11 | Lts Lohmann Therapie-Systeme Ag | Gastroretentive system with alginate body |
EP2192892A2 (en) * | 2007-07-27 | 2010-06-09 | Depomed, Inc. | Pulsatile gastric retentive dosage forms |
KR101950635B1 (en) | 2008-06-30 | 2019-05-20 | 토카겐 인크. | Formulations of 5-fluorocytosine and uses thereof |
MX340249B (en) | 2008-08-15 | 2016-07-01 | Depomed Inc | Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders. |
AU2009311877C1 (en) * | 2008-11-07 | 2013-08-15 | Samyang Holdings Corporation | Pharmaceutical composition for release control of methylphenidate |
WO2012093974A1 (en) * | 2011-01-06 | 2012-07-12 | Mahmut Bilgic | Improved bisphosphonate formulations |
CN103385871B (en) * | 2012-05-07 | 2017-06-23 | 新疆医科大学 | Benserazide micro-capsule floating tablet |
CN104334123B (en) | 2012-06-07 | 2019-02-12 | 意比图密医疗有限公司 | Expansion device |
WO2014174388A1 (en) * | 2013-03-29 | 2014-10-30 | Wockhardt Limited | Modified release pharmaceutical compositions of methylphenidate or salts thereof |
JP6204141B2 (en) * | 2013-04-22 | 2017-09-27 | テイカ製薬株式会社 | Oral rapidly disintegrating composition for solid preparation |
WO2014176389A1 (en) * | 2013-04-24 | 2014-10-30 | Temple University - Of The Commonwealth System Of Higher Education | Solid dosage form containing arabinogalactan |
US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
JP6506271B2 (en) | 2013-10-07 | 2019-04-24 | インパックス ラボラトリーズ、 インコーポレイテッドImpax Laboratories, Inc. | Mucoadhesive controlled release formulations of levodopa and / or esters of levodopa and uses thereof |
US11129793B2 (en) * | 2013-12-05 | 2021-09-28 | Epitomee Medical Ltd | Retentive devices and systems for in-situ release of pharmaceutical active agents |
EP3261625A4 (en) * | 2015-02-27 | 2018-10-24 | Cingulate Therapeutics LLC | Tripulse release stimulant formulations |
JP6823539B2 (en) * | 2017-05-26 | 2021-02-03 | 株式会社ファンケル | Gastric retention tablets |
US10588863B2 (en) | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
EP3648747B1 (en) | 2017-06-16 | 2022-09-07 | Amneal Complex Products Research LLC | Gastroretentive dosage forms for sustained drug delivery |
US10987311B2 (en) | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
ES2912968T3 (en) | 2018-06-18 | 2022-05-30 | Amneal Complex Products Res Llc | Extended Release Compositions Comprising Pyridostigmine |
WO2020006278A1 (en) | 2018-06-27 | 2020-01-02 | Kashiv Biosciences, Llc | Self-regulating osmotic gastroretentive drug delivery systems |
JP7044649B2 (en) * | 2018-06-28 | 2022-03-30 | 株式会社ファンケル | Intragastric floating tablets |
WO2020230089A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
JP2023516715A (en) * | 2020-03-02 | 2023-04-20 | クラフト ヘルス プライベート リミテッド | Method for manufacturing an oral dosage form for sustained drug release |
US11571402B2 (en) * | 2021-02-17 | 2023-02-07 | Springworks Therapeutics, Inc. | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
EP0795324A2 (en) * | 1996-02-19 | 1997-09-17 | Jagotec Ag | A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids |
WO1999004764A1 (en) * | 1997-07-23 | 1999-02-04 | Perio Products Ltd. | Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
-
2001
- 2001-06-22 IL IL15349701A patent/IL153497A0/en unknown
- 2001-06-22 AU AU6872201A patent/AU6872201A/en active Pending
- 2001-06-22 AU AU2001268722A patent/AU2001268722B8/en not_active Ceased
- 2001-06-22 WO PCT/US2001/020134 patent/WO2002000213A1/en active IP Right Grant
- 2001-06-22 CA CA002412490A patent/CA2412490A1/en not_active Abandoned
- 2001-06-22 CZ CZ2003199A patent/CZ2003199A3/en unknown
- 2001-06-22 JP JP2002504995A patent/JP2004501190A/en active Pending
- 2001-06-22 EA EA200300046A patent/EA200300046A1/en unknown
- 2001-06-22 HU HU0301465A patent/HUP0301465A3/en unknown
- 2001-06-22 KR KR1020027017538A patent/KR20030013460A/en not_active Application Discontinuation
- 2001-06-22 EP EP01946709A patent/EP1305021A4/en not_active Withdrawn
- 2001-06-22 MX MXPA02012793A patent/MXPA02012793A/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
EP0795324A2 (en) * | 1996-02-19 | 1997-09-17 | Jagotec Ag | A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids |
WO1999004764A1 (en) * | 1997-07-23 | 1999-02-04 | Perio Products Ltd. | Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
Non-Patent Citations (1)
Title |
---|
See also references of WO0200213A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2001268722B2 (en) | 2005-08-11 |
AU6872201A (en) | 2002-01-08 |
EA200300046A1 (en) | 2003-10-30 |
MXPA02012793A (en) | 2004-07-30 |
CA2412490A1 (en) | 2002-01-03 |
AU2001268722B8 (en) | 2005-09-29 |
JP2004501190A (en) | 2004-01-15 |
IL153497A0 (en) | 2003-07-06 |
EP1305021A1 (en) | 2003-05-02 |
KR20030013460A (en) | 2003-02-14 |
WO2002000213A1 (en) | 2002-01-03 |
HUP0301465A2 (en) | 2004-05-28 |
HUP0301465A3 (en) | 2006-07-28 |
CZ2003199A3 (en) | 2003-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6872201A (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
AU8405201A (en) | Contraception process and administration form for the same | |
HUP0301325A3 (en) | Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition | |
MXPA03003895A (en) | Controlled release hydrocodone formulations. | |
HUP0301242A3 (en) | Controlled release drug dosage form | |
AU2001253479A1 (en) | Targeted therapeutic agent release devices and methods of making and using the same | |
IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
AU2001280597A1 (en) | Compositions for sustained release of analgesic agents, and methods of making and using the same | |
MXPA02004770A (en) | Therapeutic compositions and methods of use thereof. | |
IL153708A0 (en) | Benzimidazole derivatives, preparation and therapeutic use thereof | |
IL151890A0 (en) | Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain | |
AU2002360717A1 (en) | Controlled release dosage form having improved drug release properties | |
GB0002386D0 (en) | Therapeutic composition | |
FI20000780A (en) | Oral dosage form for controlled release of the drug | |
MXPA03004303A (en) | Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain. | |
EP1501352A4 (en) | Methods and compositions for controlled release of drugs | |
IL151891A0 (en) | Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain | |
PL357812A1 (en) | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain | |
HUP0102159A3 (en) | Pharmaceutical composition for the treatment of rumen acidosis | |
HUP0204417A3 (en) | Oral ciprofloxacin-composition of controlled release | |
GB0030067D0 (en) | Therapeutic agent | |
EP1357898A4 (en) | Improved controlled release oral dosage form | |
HK1046848A1 (en) | Specific therapeutic composition for treating aids | |
HK1055954A1 (en) | Crystalline therapeutic agent. | |
IL135993A0 (en) | Pharmaceutical composition for the treatment of fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030121 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090825 |
|
17Q | First examination report despatched |
Effective date: 20100816 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20101228 |